Basecamp Research has successfully raised $140 million in a Series C funding round, with the funds designated for advancing drug candidates created using artificial intelligence. This re-signed round was led by S32, and supported by major investors from the technology and healthcare sectors.
Participants in the round included Anthology Fund from Anthropic, NVIDIA, Catalio Capital Management, and True Ventures. Additional investors comprised NATO Innovation Fund, Redalpine, Singular, and The Rockefeller Foundation. The London-based company intends to use the capital to train new EDEN models and to advance its portfolio of AI-developed therapeutics into clinical trials.
Basecamp Research was founded in 2019 by Glenn Goers and Timothy Hyde. Goers serves as co-founder and CEO. The company's objective is to develop medications capable of reprogramming the body for self-repair. Their approach integrates advanced AI models with proprietary biological data and DNA sequencing technology.
The company applies its EDEN biological foundational models for in vivo cell therapy. This methodology aims at directly reprogramming a patient's cells within the body. Existing cell therapy methods often require complex manufacturing processes and significant per-patient costs.
Basecamp seeks to simplify this process through AI-designed genetic payloads. The company's technology enables the creation of long and complex DNA sequences for therapeutic use. Furthermore, the company develops large serine recombinases capable of precisely integrating these sequences.
This combination can make cell therapies more sophisticated and customizable. Potential applications include the treatment of cancer, autoimmune diseases, and other conditions. Basecamp claims to have already achieved compelling preclinical results across multiple modalities.
At the core of Basecamp's AI platform is its Atlas of Trillion Genes. The company describes it as the world's largest proprietary dataset for training biological AI. According to Basecamp's website, this dataset contains over 100 billion novel genes. It was compiled through biodiversity partnerships spanning more than 30 countries and including biological samples from all seven continents. Basecamp developed the Atlas in collaboration with partners such as NVIDIA, Anthropic, PacBio, and Ultima Genomics.
The acquired dataset grants EDEN models access to previously unseen biological patterns. These models are designed to understand DNA function across various life forms and to generate potential therapeutic candidates based on disease information. Application areas include cell and gene therapy, enzymes, and peptides. Basecamp demonstrated this approach in collaboration with Anthropic on the Claude Science project. The Series C round marks a transition from biological data collection to therapeutic development. The company has not yet announced a date for its first clinical trial.
Basecamp now plans to transform its biological intelligence into potential medicines. Its six-program portfolio will allow testing the technology across various diseases. The company also intends to expand pharmaceutical partnerships around its platform.
Richard Pierce has joined as Chief Business Officer to support these efforts. Pierce previously held a senior position at Biogen. Andy Conrad, Managing Partner at S32, will also join Basecamp's board of directors. Previously, he led Google's Verily.
The round also attracted senior executives from pharmaceutical and biotechnology companies. Among the additional investors was Roche Vice Chairman Andre Hoffmann. Basecamp states that its platform can help reduce the manufacturing requirements for future cell therapies. The company's headquarters are in London, with laboratories located in Cambridge, Massachusetts. The company's long-term goal is to use AI to develop drugs for previously intractable diseases. Its portfolio includes three in vivo CAR-T programs and other therapeutic projects.